Kbc Group Nv Supernus Pharmaceuticals, Inc. Transaction History

Kbc Group Nv

$36.3 Billion
Q4 2024

A detailed history of Kbc Group Nv transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 2,679 shares of SUPN stock, worth $104,481. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,679

Previous 1,750 53.09%

Holding current value

$104,481

Previous $55,000 76.36%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 22, 2025	BUY	$31.89 - $37.83 $29,625 - $35,144	929 Added 53.09%	2,679 $97,000
Q3 2024 Nov 06, 2024	SELL	$25.77 - $35.16 $644 - $878	-25 Reduced 1.41%	1,750 $55,000
Q4 2023 Feb 13, 2024	SELL	$22.72 - $29.68 $53,914 - $70,430	-2,373 Reduced 57.21%	1,775 $51,000
Q3 2023 Feb 15, 2024	SELL	$27.57 - $32.91 $65,423 - $78,095	-2,373 Reduced 57.21%	1,775 $49,000
Q2 2023 Feb 15, 2024	SELL	$29.91 - $38.73 $13,339 - $17,273	-446 Reduced 9.71%	4,148 $125,000
Q2 2023 Jul 28, 2023	SELL	$29.91 - $38.73 $13,339 - $17,273	-446 Reduced 9.71%	4,148 $125,000
Q3 2022 Feb 15, 2024	BUY	$28.79 - $35.41 $81,159 - $99,820	2,819 Added 158.82%	4,594 $156,000
Q2 2022 Feb 14, 2024	BUY	$25.33 - $34.25 $71,405 - $96,550	2,819 Added 158.82%	4,594 $133,000
Q2 2022 Jul 26, 2022	BUY	$25.33 - $34.25 $116,366 - $157,344	4,594 New	4,594 $133,000
Q1 2020 May 04, 2020	SELL	$14.45 - $24.69 $196,404 - $335,586	-13,592 Closed	0 $0
Q3 2019 Nov 07, 2019	SELL	$25.47 - $33.37 $227,115 - $297,560	-8,917 Reduced 39.62%	13,592 $373,000
Q1 2019 May 10, 2019	BUY	$32.77 - $41.99 $432,662 - $554,393	13,203 Added 141.88%	22,509 $0
Q2 2018 Aug 03, 2018	SELL	$44.1 - $59.85 $840,193 - $1.14 Million	-19,052 Reduced 67.18%	9,306 $0
Q3 2017 Nov 13, 2017	BUY	$36.75 - $49.65 $1.04 Million - $1.41 Million	28,358	28,358 $0

Others Institutions Holding SUPN

# of Institutions

284

Shares Held

60.5M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.09B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.

Account